Cherubism

Subscribe to Selected New Research on Cherubism

30 relevant articles (0 outcomes, 2 trials/studies) found for this Disease

Description: A fibro-osseous hereditary disease of the jaws. The swollen jaws and raised eyes give a cherubic appearance; multiple radiolucencies are evident upon radiographic examination.

Disease Context: Research Results

Musculoskeletal Diseases: 83

Bone Diseases: 2383

Developmental Bone Diseases: 63

Osteochondrodysplasias: 374

Fibrous Dysplasia of Bone: 38

Cherubism: 30

Jaw Diseases: 7

Cherubism: 30

Stomatognathic Diseases: 250

Jaw Diseases: 7

Cherubism: 30

Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 422

Congenital Abnormalities: 9330

Musculoskeletal Abnormalities: 17

Craniofacial Abnormalities: 63

Maxillofacial Abnormalities: 5

Cherubism: 30

Inborn Genetic Diseases: 549

Cherubism: 30

Related Diseases

1.	Inflammation
2.	Syndrome
3.	Osteoporosis
4.	Bone Resorption
5.	X-Linked Dominant Hypophosphatemic Rickets (X-Linked Hypophosphatemia)

Experts

1.	de Lange, Jan: 1 article (08/2007)
2.	Scholtemeijer, Marcel: 1 article (08/2007)
3.	van den Akker, Hans P: 1 article (08/2007)
4.	Ebihara, Takeshi: 1 article (01/2007)
5.	Mukherjee, Padma M: 1 article (01/2007)
6.	Lin, Chin-Yu: 1 article (01/2007)
7.	Senoo, Makoto: 1 article (01/2007)
8.	Onji, Masahiro: 1 article (01/2007)
9.	Olsen, Bjorn R: 1 article (01/2007)
10.	Saheki, Yasunori: 1 article (01/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cherubism:

1.	Calcitonin (Calcitonin, Eel)FDA Link 11/01/1998 - "AIMS: To establish whether the multinucleate cells in lesions of patients with cherubism are also osteoclasts and if this is the case whether they were responsive to calcitonin; to carry out cytogenetic studies on two members of the same family affected by cherubism in an attempt to identify any major chromosomal defects; and to perform an in-depth modern biochemical study of four children in the same family" 08/01/2007 - "Cherubism treated with calcitonin: report of a case." 11/01/1998 - "The biochemistry profile of all four children with cherubism showed that serum calcium, parathyroid hormone, parathyroid related hormone, calcitonin, and alkaline phosphatase were within normal levels" Order ALL the reference details at left...
2.	Adenosine Triphosphatases (ATPase)IBA 07/01/2003 - "METHODS: Immunohistochemical study with a panel of antibodies including vacuolar H+-ATPase (V-ATPase), carbonic anhydrase II (CA II), Cathepsin K, matrix metalloproteinases-9 (MMP-9), CD68, and proliferating cell nuclear antigen (PCNA), and enzyme histochemical staining for tartarate-resistant acid phosphatase (TRAP) were applied on a total number of 53 cases of giant cell-containing lesions including CGCG (n = 34), PGCG (n = 6), cherubism (n = 7), and ABC (n = 6)" 06/01/2005 - "The 20 genes with at least a 3-fold change, annotated with known phenotypic associations in the current gene databank (phenotype association, fold change) were aspartoacylase (Canavan disease, 9.96), growth hormone receptor (Laron dwarfism, idiopathic short stature, 8.25), lipoprotein lipase (familial chylomicronemia syndrome, lipoprotein lipase deficiency, 8.00), vitamin D (1,25- dihydroxyvitamin D3) receptor (involutional osteoporosis, vitamin D resistant rickets, 7.94), intercellular adhesion molecule 1 human rhinovirus receptor (cerebral malaria susceptibility, 7.16), peroxisomal membrane protein 3 35-kDa (Refsum disease, infantile form, Zellweger syndrome-3, 6.00), Bardet-Biedl syndrome 2 (Bardet-Biedl syndrome, 5.87), ribosomal protein S19 (Diamond Blackfan anemia, 5.85), apolipoprotein C-III (hypertriglyceridemia, 5.44), argininosuccinate lyase (argininosuccinicaciduria, 5.22), myosin VA (Griscelli syndrome-type pigmentary dilution with mental retardation, 4.92), lysozyme (renal amyloidosis, 4.17), SAM domain, SH3 domain and nuclear localisation signals 1 (Cherubism, 4.12 ), von Hippel-Lindau syndrome (hemangioblastoma, cerebellar, somatic, von Hippel-Lindau syndrome, 3.94), early-onset breast cancer 1 (BRCA1, papillary serous carcinoma of the peritoneum, 3.73), UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (inclusion body myopathy, autosomal recessive, sialuria, 3.53), apolipoprotein A-I (amyloidosis, 3 or more types, hypoalphalipoproteinemia, 3.29), midline 1 Opitz/BBB syndrome (Opitz G syndrome, type I, 3.28), ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide (familial hemiplegic migraine, 3.05)" Order ALL the reference details at left...
3.	Vacuolar Proton-Translocating ATPases (V-Type ATPase)IBA 07/01/2003 - "METHODS: Immunohistochemical study with a panel of antibodies including vacuolar H+-ATPase (V-ATPase), carbonic anhydrase II (CA II), Cathepsin K, matrix metalloproteinases-9 (MMP-9), CD68, and proliferating cell nuclear antigen (PCNA), and enzyme histochemical staining for tartarate-resistant acid phosphatase (TRAP) were applied on a total number of 53 cases of giant cell-containing lesions including CGCG (n = 34), PGCG (n = 6), cherubism (n = 7), and ABC (n = 6)" Order ALL the reference details at left...
4.	Carbonic Anhydrase IIIBA 07/01/2003 - "METHODS: Immunohistochemical study with a panel of antibodies including vacuolar H+-ATPase (V-ATPase), carbonic anhydrase II (CA II), Cathepsin K, matrix metalloproteinases-9 (MMP-9), CD68, and proliferating cell nuclear antigen (PCNA), and enzyme histochemical staining for tartarate-resistant acid phosphatase (TRAP) were applied on a total number of 53 cases of giant cell-containing lesions including CGCG (n = 34), PGCG (n = 6), cherubism (n = 7), and ABC (n = 6)" Order ALL the reference details at left...
5.	Proliferating Cell Nuclear Antigen (PCNA)IBA 07/01/2003 - "METHODS: Immunohistochemical study with a panel of antibodies including vacuolar H+-ATPase (V-ATPase), carbonic anhydrase II (CA II), Cathepsin K, matrix metalloproteinases-9 (MMP-9), CD68, and proliferating cell nuclear antigen (PCNA), and enzyme histochemical staining for tartarate-resistant acid phosphatase (TRAP) were applied on a total number of 53 cases of giant cell-containing lesions including CGCG (n = 34), PGCG (n = 6), cherubism (n = 7), and ABC (n = 6)" Order ALL the reference details at left...
6.	AntibodiesIBA 07/01/2003 - "METHODS: Immunohistochemical study with a panel of antibodies including vacuolar H+-ATPase (V-ATPase), carbonic anhydrase II (CA II), Cathepsin K, matrix metalloproteinases-9 (MMP-9), CD68, and proliferating cell nuclear antigen (PCNA), and enzyme histochemical staining for tartarate-resistant acid phosphatase (TRAP) were applied on a total number of 53 cases of giant cell-containing lesions including CGCG (n = 34), PGCG (n = 6), cherubism (n = 7), and ABC (n = 6)" Order ALL the reference details at left...
7.	Acid PhosphataseIBA 07/01/2003 - "METHODS: Immunohistochemical study with a panel of antibodies including vacuolar H+-ATPase (V-ATPase), carbonic anhydrase II (CA II), Cathepsin K, matrix metalloproteinases-9 (MMP-9), CD68, and proliferating cell nuclear antigen (PCNA), and enzyme histochemical staining for tartarate-resistant acid phosphatase (TRAP) were applied on a total number of 53 cases of giant cell-containing lesions including CGCG (n = 34), PGCG (n = 6), cherubism (n = 7), and ABC (n = 6)" Order ALL the reference details at left...
8.	cathepsin K (cathepsin O)IBA 07/01/2003 - "METHODS: Immunohistochemical study with a panel of antibodies including vacuolar H+-ATPase (V-ATPase), carbonic anhydrase II (CA II), Cathepsin K, matrix metalloproteinases-9 (MMP-9), CD68, and proliferating cell nuclear antigen (PCNA), and enzyme histochemical staining for tartarate-resistant acid phosphatase (TRAP) were applied on a total number of 53 cases of giant cell-containing lesions including CGCG (n = 34), PGCG (n = 6), cherubism (n = 7), and ABC (n = 6)" Order ALL the reference details at left...
9.	Carrier Proteins (Binding Protein)IBA 06/01/2007 - "Germline mutations in exon 9 of the gene encoding Src homology 3 binding protein 2 (SH3BP2) occur in most patients with cherubism" 08/15/2003 - "Cherubism is a rare autosomal dominant inherited condition caused by mutations in the c-Abl-binding protein SH3BP2" 08/15/2003 - "Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism." 06/01/2001 - "Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism." 01/12/2007 - "Mutations in the SH3-domain binding protein 2 (SH3BP2) are known to cause a rare childhood disorder called cherubism that is characterized by inflammation and bone loss in the jaw, but the mechanism has remained unclear" Order ALL the reference details at left...
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/12/2007 - "We demonstrate that Sh3bp2 "cherubism" mice exhibit trabecular bone loss, TNF-alpha-dependent systemic inflammation, and cortical bone erosion" 01/12/2007 - "In this issue, Ueki et al. (Ueki et al., 2007) now demonstrate that a cherubism mutation activates mouse Sh3bp2 resulting in enhanced production of the cytokine TNF-alpha by myeloid cells, leading to both bone loss and inflammation." 11/01/2008 - "Cherubism mice", which carry a gain-of-function mutation in SH3-domain binding protein 2 (Sh3bp2), develop osteoporosis and widespread inflammation dependent on the proinflammatory cytokine, TNF-alpha" Order ALL the reference details at left...

Therapies and Procedures

1.	Curettage 06/01/2007 - "Although cherubism tends to abate by the fourth decade of life, early 2-stage surgical curettage provides a simple and reliable treatment that not only delivers immediate results, but also seems to arrest the growth of any remaining cherubic tissue." 06/01/2005 - "Of these, no treatment was carried out in five cases, cherubism resolved (three cases) or grew slowly (two cases); curettage or surgical contouring was performed in seven cases, during the rapid growth of the lesions" 07/01/1967 - "Cherubism treated by curettage and autogenous bone chips: report of case." 11/01/2007 - "Histologically identical lesions occur in patients with known genetic defects such as cherubism, Noonan syndrome, or neurofibromatosis type 1. Surgical curettage or, in aggressive lesions, resection, is the most common therapy" Order ALL the reference details at left...
2.	Transplants (Transplant) 04/01/1985 - "We had the chance to operate on a 5-year-old boy with cherubism 8 years ago, and used homogenous bone grafts to replace the diseased tissue to avoid pathological fracture of the mandible" 08/01/1978 - "Homogenous bone grafts were used in 20 cases including cysts, nonunions, an open bite, an ameloblastoma, fibrous dysplasia, and cherubism" Order ALL the reference details at left...
3.	Lipectomy (Liposuction) 11/01/1990 - "Yet another application of suction lipectomy equipment is presented to remove the pathologic tissue in cherubism" 11/01/1990 - "The use of liposuction to contour cherubism." Order ALL the reference details at left...
4.	Fixed Partial Denture (Pontic) 11/01/2006 - "This clinical report describes the fabrication of maxillary fixed partial dentures and a mandibular overdenture for a 21-year-old man with cherubism." Order ALL the reference details at left...
5.	Overlay Denture 11/01/2006 - "This clinical report describes the fabrication of maxillary fixed partial dentures and a mandibular overdenture for a 21-year-old man with cherubism." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Cherubism

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 0 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>